Home > Insider Trading > Filing (0001144204-12-030419)

Filing Details

Accession Number:: 0001144204-12-030419
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2012-05-17 13:00:00
Reporting Period:: 2012-04-30

Filing Date:: 2012-05-17
Accepted Time:: 2012-05-17 17:32:50
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1001316	Tg Therapeutics Inc.	TGTXD	Pharmaceutical Preparations (2834)	363898269

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1038977	S Michael Weiss	787 Seventh Avenue, 48Th Floor New York NY 10019	See Remarks	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2012-04-30	3,524,560	$0.00	3,691,228	No	4	C	Direct
Common Stock	Acquisiton	2012-05-16	1,500,000	$0.00	5,191,228	No	4	A	Direct
Common Stock	Acquisiton	2012-05-16	1,500	$6.25	5,192,728	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	A	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	SERIES A PREFERRED STOCK	Disposition	2012-04-30	396,513	$0.00	396,513	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct

Footnotes

The Series A convertible Preferred Stock converted into issuer common stock on a 500-for-1 basis and had no expiration date.
Reflects a grant of restricted shares that will vest according to the following schedule: 50% in equal installments on the 3rd, 4th, and 5th anniversary of the date of grant; 25% on the first date that the issuer achieves a pre-established market capitalization target; and 25% on the first date that the issuer achieves another pre-established market capitalization target.
Includes 1,000,000 shares of Common Stock, which vest as follows: 125,000 on each of November 15, 2012, November 15, 2013, November 15, 2014, and November 15, 2015; 250,000 upon the occurrence of the registrant achieving a particular market capitalization target; and 250,000 upon the occurrence of the registrant achieving a second particular market capitalization target. In addition, Mr. Weiss purchased shares in the Offering conducted by the Company which closed on December 30, 2011. As a result of that purchase he owns 133,334 shares of our Common Stock, and 33,334 warrants to purchase Common Stock at $2.25, exercisable for five years. Finally, also included in Mr. Weiss' beneficial ownership are 2,524,560 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest.
On April 30, 2012, the issuer effected a reverse stock split, pursuant to which every 56.25 shares of common stock issued and outstanding immediately prior to the effective time of the reverse stock split automatically combined into one share of common stock, resulting in Mr. Weiss' ownership of 203,940,273 less shares of common stock. The figures outlined above reflect the post-split holdings of Mr. Weiss.